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B
ACKGROUND: An organism’s lifespan is 
inevitably accompanied by the aging process, 
which involves functional decline, a steady 
increase of a plethora of chronic diseases, and ultimately 
death. Thus, it has been an ongoing dream of mankind to 
improve healthspan and extend life.
CONTENT: There are only a few proposed aging 
interventions: caloric restriction, exercise, and the use of 
low-molecular-weight compounds, including spermidine, 
metformin, resveratrol, and rapamycin. Resveratrol, a 
constituent of red wine, has long been suspected to have 
cardioprotective effects. Interest in this compound has been 
renewed in recent years, irst from its identiication as a 
chemopreventive agent for skin cancer, and subsequently 
from reports that it activates sirtuin deacetylases and 
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extends the lifespans of lower organisms. Resveratrol have 
been shown to prevent and reduce the severity of age-related 
diseases such as atherosclerosis, stroke, myocardial infarct, 
diabetes, neurodegenerative diseases, osteoarthritis, tumors 
and metabolic syndrome, along with their ability to extend 
lifespan.
SUMMARY: The purpose of aging research is the 
identiication of interventions that may avoid or ameliorate 
the ravages of time. In other words, the quest is for 
healthy aging, where improved longevity is coupled to a 
corresponding healthspan extension. It is only by extending 
the healthy human lifespan that we will truly meet the 
premise of the Roman poet Cicero: “No one is so old as to 
think that he may not live a year.”
KEYWORDS: aging, caloric restriction, mimetic, 
healthspan, sirtuin activator
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Introduction
For thousands of years humanity has searched for the 
fountain of youth. In the 16th century the Spanish explorer 
Juan Ponce de León, irst Governor of Puerto Rico, searched 
for the fountain of youth in the legendary land of Florida, 
speciically in the waters of Bimini, but without success. 
This quest continues, although all living species on our 
planet are designed to age. A fountain-of-youth strategy 
has been proposed by several investigators during recent 
decades. This strategy to slow down the aging processes 
is based on caloric restriction (CR) and increased physical 
activity.(1)
 The reduction in the intake of calories without 
malnutrition is deined as CR. Such reduction ideally 
corresponds to a decrease of approximately 30% of calories 
per day, at least in mice. In humans, there is some indication 
that a CR of around 15% may be most favorable against 
mortality during aging.(2) One of the best correlations 
between CR and improvement in healthspan and prolonged 
life in humans is the long-lived population in Okinawa, 
Japan.(3) In comparison to the rest of the Japanese 
population, Okinawan people usually combine an above-
average amount of daily exercise with a below-average food 
intake.(2) However, when Okinawan families moved to 
Brazil, they adopted a Western lifestyle that impacted both 
their diet and physical activity, resulting in increased weight 
gain and a drop in life expectancy of 17 years.(3) CR changes 
many parameters in the aging human body, including 
the transcriptome, the hormonal status (in particular the 
serum concentration of Insulin-like Growth Factor (IGF)-
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1 and thyroid hormones), oxidative stress, inlammation, 
mitochondrial function, and glucose homeostasis.(4,5)
 Recent discoveries, however, have focused attention 
towards interesting molecules able to increase lifespan and 
prevent age-related diseases. These molecules are called 
sirtuin (SIRT). The mammalian SIRT 1–7 belong to a 
family of histone deacetylases, named for their homology 
to the Saccharomyces cerevisiae gene silent information 
regulator  (Sir)2. SIRT require nicotinamide adenine 
dinucleotide (NAD+) as a cofactor to deacetylate substrates 
ranging from histones to transcriptional regulators.(6) An 
increasing number of studies clearly reported that activation 
of SIRT, especially SIRT1 and SIRT3, increases longevity 
by mimicking the beneicial effects of CR. Moreover, recent 
indings have suggested that moderate prolonged exercise 
training is able to increase SIRT1 activity in aged animals, 
counteracting age-related dysfunctions.(7) Does taking 
SIRT’s activators produce the same effect as drinking water 
from the legendary fountain of youth? This is the main 
question that several scientists worldwide are trying to 
answer.(1)
 Resveratrol is a polyphenol that is found in grapes 
and in red wine. Its potential to promote lifespan was 
irst identiied in yeast (8), and it has since gained fame 
because it was suggested to be responsible for the so-called 
French paradox (French winemakers do not suffer from 
cardiovascular diseases though enjoying a high-fat diet) 
(5). Overall, it is clear that resveratrol treatment or SIRT1 
overexpression prevents several age-associated diseases 
and pathogenic conditions, including oxidative stress in the 
aging heart, neurodegeneration, or diabetes.(9) Importantly, 
activation of autophagy by resveratrol is required for 
lifespan extension in Caenorhabditis elegans (C. elegans).
(5,10)
The more complex a problem, the more important it may be 
to ask simple questions. So, why do we age? Actually, we 
do hold the capacity for immortality. The molecular clock in 
our germline stem cells, which sustain gamete production, is 
kept at zero as evidenced by the fact that our offspring are not 
born with the father’s or mother’s age. Then why do somatic 
cells age? First, the maintenance of repair activity in all our 
cells represents a vast energetic demand and, second, the 
pressure of recombination and dying of generations allows 
organisms to adapt to changing environments (e.g., ice 
ages). This implies that aging may be an atavistic, adaptive 
and altruistic program, by which single cells or organisms 
eventually die for the beneit of the whole population in a 
highly coordinated (programmatic) fashion.(5)
 A hallmark of aging is compromised tissue 
maintenance.(11) Tissue-speciic stem cells self-renew 
and persist throughout an organism’s lifespan to repair 
and maintain tissues. The self-renewal potential and 
differentiation capacity of stem cells become dysregulated 
with age.(12,13) Stem cell aging is thought to be due to 
cumulative cellular and genomic damages, resulting in 
permanent cell-cycle arrest, apoptosis, or senescence.(12-
14) A major source of cellular damage is reactive oxygen 
species (ROS), a natural by-product of cellular respiration.
(15) ROS levels in stem cells increase dramatically with 
age.(16) Deicient intracellular management of ROS results 
in increased stem cell cycling and apoptosis, as well as 
compromised self-renewal and differentiation, resembling 
essential aspects of aged stem cells.(17-21)
 The study by Brown, et al. provides important insights 
into mitochondrial metabolism in stem cell maintenance 
and illuminates the previously underappreciated plasticity 
of mitochondrial homeostasis in stem cell maintenance 
and tissue homeostasis during the aging process. Using 
oxidative stress as a readout for various mitochondrial 
processes regulated by SIRT3, they show that SIRT3-
mediated mitochondrial homeostasis is essential for 
HSC maintenance under stress and that this regulatory 
program is downregulated with age. Together, these data 
suggest that suppression of SIRT3-mediated mitochondrial 
homeostasis contributes to increased oxidative stress in 
aged hematopoietic stem cell (HSC). This regulatory 
process complements the view that passive accumulation of 
damaged mitochondria with age results in increased ROS 
and underlies the plasticity of mitochondrial homeostasis in 
stem cell maintenance and tissue homeostasis.(22)
 According to the World Health Organization (WHO), 
age itself remains the greatest risk factor for all major life-
threatening disorders, and the number of people suffering 
from age-related diseases is anticipated to almost double 
over the next two decades. The fact that healthspan has 
not increased at the same pace as lifespan is a source of 
grave concern.(23) Both obesity and hypertension represent 
major risk factors for stroke and cardiovascular disease. 
Although weight loss and increase in physical activity are 
generally prescribed to avoid such age-associated diseases, 
only a small percentage of people have the discipline to 
change their lifestyle accordingly.(24) The prevalence of 
age-related pathologies represents major psychological 
and social impediments as well as an economic burden that 
urgently needs appropriate interventions.(5)
 Over three quarters of deaths from cardiovascular 
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diseases occur among patients over 65 years of age.
(25) Epidemiological studies show that even in the 
absence of risk factors related to lifestyle (e.g., obesity, 
hypercholesterolemia, smoking), advanced age, per se, 
promotes the development of cardiovascular disease.(26) In 
order to develop novel therapeutic interventions to promote 
vascular health in older persons, it is essential to understand 
the mechanisms through which aging impairs homeostatic 
mechanisms in the vasculature.(27) Vascular oxidative stress 
and inlammation are thought to promote the development 
of atherosclerotic vascular diseases (including myocardial 
infarction, stroke, and vascular dementias), increasing 
cardiovascular mortality in elderly patients.(26)
 Viewing the reality of aging from the arterial wall 
begins with the realization that arterial diseases, e.g. 
atherosclerosis and hypertension, are rampant in modern 
society, and increase exponentially with advancing age. 
Progressive changes occur throughout life in the structure 
and function of central arteries in numerous species. These 
changes include diffuse intimal and medial thickening, 
and enhanced stiffening.(28) Since the likelihood for 
predominantly systolic hypertension and atherosclerosis 
to occur increases in epidemic proportion among older 
persons.(28,29) it is reasonable to hypothesize that speciic 
mechanisms that underlie alterations in the arterial substrate 
that accompany “aging” may be intimately linked to the age-
associated exponential increase in predominantly systolic 
hypertension.(30)
 Central arterial aging is a hallmark of systems 
aging, and can be viewed as the failure of key signaling 
pathways to execute crucial functions.(30) These aging – 
related changes in the molecular and cellular functions of 
key signaling systems facilitate adverse central arterial 
remodeling, such as diffuse intima – media thickening, 
enhanced stiffening, and endothelial dysfunction.(28,31-33) 
Arterial wall aging begins with chronic proinlammation, a 
form of ‘sterile-like’ inlammation that occurs in the absence 
of any microorganisms and with little or no white blood cell 
iniltration. Phenotypic shifts in arterial endothelial cell and 
vascular smooth muscle cell (VSMC) promote pathogenic 
inlammation.(28,31-33) This is why arterial aging dwarfs 
other risk factors for clinical manifestations and severity of 
hypertension and atherosclerosis.(34)
Nutrition is among the most important means for mitigating 
age-associated chronic diseases. By some estimates, 80% of 
coronary heart disease (CHD) and type-2 diabetes mellitus 
and 40% of cancers may be prevented by modifying dietary 
habits, engaging in regular physical activity, and avoiding 
tobacco use.(35-37) The Okinawans are of special interest 
to this topic as they, by most measures, have the world’s 
longest-lived population, and nutritional factors appear to 
have played a key role.(38-40) The chronic disease proile 
of the older Okinawan population is especially impressive, 
with 80% less CHD mortality and 40% less cancer mortality 
than the US population.(38) Some attribute the healthy aging 
phenomenon in Okinawa principally to nutritional factors, 
and CR is thought to be one key factor.(38,39,41,42)
 CR is the only regimen known to extend the life span 
and health span in a spectrum of organisms that include 
yeast, mice, and nonhuman primates.(43-45) Reducing food 
consumption 25-60% without undernutrition extends the life 
span of rodents up to 50% (45) and in different animal models 
delays the onset of age-related maladies, like cardiovascular 
disease, cancer, and diabetes (43,46). The positive effects 
of CR are linked to major metabolic reprogramming toward 
eficient fuel utilization and a reduction in oxidative damage 
to macromolecules.(47,48) Long-term CR in humans 
inhibits the IGF-1/insulin pathway in skeletal muscle, a key 
metabolic tissue. CR also induces dramatic changes of the 
skeletal muscle transcriptional proile that resemble those 
of younger individuals. Finally, in both rats and humans, 
CR evoked similar responses in the transcriptional proiles 
of skeletal muscle. This common signature consisted of 
three key pathways typically associated with longevity: 
IGF-1/insulin signaling, mitochondrial biogenesis, and 
inlammation.(49)
 Mitochondrial dysfunction plays an important role in 
cellular aging (50) and reduces fuel utilization plasticity. As 
metabolic centers for fuel utilization and primary producers 
of cellular ROS, mitochondria are poised to act as mediators 
of reprogramming under CR. However, the molecular basis 
for global metabolic adaptation induced by CR remains 
unknown.(51)
 Fasting has been practiced for millennia, but, only 
recently, studies have shed light on its role in adaptive 
cellular responses that reduce oxidative damage and 
inlammation, optimize energy metabolism, and bolster 
cellular protection. In lower eukaryotes, chronic fasting 
extends longevity, in part, by reprogramming metabolic 
and stress resistance pathways. In rodents intermittent or 
periodic fasting protects against diabetes, cancers, heart 
disease, and neurodegeneration, while in humans it helps 
reduce obesity, hypertension, asthma, and rheumatoid 
arthritis. Thus, fasting has the potential to delay aging and 
help prevent and treat diseases while minimizing the side 
effects caused by chronic dietary interventions.(52)
CR, Exercise and Mimetics
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 The traditional Okinawan diet is a rich source for 
potential CR mimetics. In the Okinawan language, the term 
“nuchi gusui”, a term in common use, literally means ‘food is 
medicine’ as commonly consumed dietary items, including 
foods, herbs, and spices are also used as folk medicines.(53) 
Popular items that play dual roles as foods and traditional 
medicines are sweet potatoes (pulp, skin, and leaves), bitter 
melon, turmeric, ginger, mugwort (Artemisia vulgaris), 
peppers (Piper hancei), and carotenoid-rich marine foods, 
among others.(2) Compounds that have potential CR 
mimetic properties, such as carotenoids, lavonoids, and 
other phytochemicals, are synthesized (mostly by plants) 
to help scavenge-free radicals formed due to stress from 
extremes of heat, cold, or ultraviolet light. As the sun in 
Okinawa is particularly strong many locally grown plants 
contain high quantities of these phytochemicals.(54)
 While CR increases lifespan, studies support more of a 
beneicial role for exercise on healthspan.(23) Although CR 
and exercise have similar effects, clearly disparities exist 
between these two interventions, with potential molecular 
mechanisms excellently reviewed by Huffman.(55)  Despite 
not altering lifespan, regularly performed moderate exercise 
will delay certain age-associated changes and protect 
against several metabolic disorders.(56) Previous research 
has shown that exercise is associated with greater beneits 
than CR, or vice versa. The most noticeable health beneits 
of exercise over CR are maintenance of aerobic capacity, 
muscle mass and muscle strength, and an improved bone 
health.(57,58) As a consequence, regularly performed 
exercise has a stronger impact particularly in cardiovascular 
disease, diabetes and osteoporosis. Therefore, as pointed 
out by Huffman, et al., the effect of exercise may be more 
pronounced in humans, who perish more from cardiovascular 
disease, than in animal models that primarily die of renal 
disease or cancers.(59) Additionally, as aging is associated 
with a decline in physical activity, regular physical activity 
plays an essential role in the elderly by lessening disability 
and prolonging independent living.(60) Taken together, 
these indings provide compelling evidence that regularly 
performed exercise is associated with an improved quality 
of life, without slowing the aging process.(23)
Sir2 family proteins, now called SIRT, have been 
demonstrated to coordinate metabolic responses to changes 
in nutritional availability and maintain physiological 
homeostasis in mammals.(61) These functions of SIRT 
are ascribed to their unique NAD-dependent enzymatic 
activities (62), placing SIRT at the perfect position to 
integrate energy metabolism information into many other 
biological regulations. In particular, the mammalian Sir2 
ortholog SIRT1 plays a critical role for the regulation of 
metabolic responses in multiple tissues, including the 
liver, skeletal muscle, adipose tissue, and brain, through 
its deacetylase activity.(61) SIRT1 also plays a role in the 
regulation of phenotypes induced by CR, a diet regimen 
Figure 1.  SIRT deacetylation and ADP-ribosylation 
reactions. Both deacetylation and ADP-ribosylation 
occur via cleavage of NAD to release nicotinamide.
(9) (Adapted with permission from Cold Spring Harbor 
Laboratory Press).
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that delays aging and extends life span in a wide variety of 
organisms.(61)
 SIRT1 is the closest to yeast Sir2 in terms of sequence 
and enzymatic activity, and is also the most extensively 
studied mammalian SIRT having numerous known 
substrates, including peroxisome proliferator-activated 
receptor gamma coactivator 1-alpha (PGC-1α), nuclear 
factor kappa-light-chain-enhancer of activated B cells 
(NFκB), p53 and forkhead box O (FOXO)1.(63-66) SIRT1 
is an important regulator of metabolism. SIRT1 upregulates 
mitochondrial biogenesis in several tissues, stimulates fat 
and cholesterol catabolism in liver, skeletal muscle and 
adipose tissue.(67) In addition, liver glucose metabolism 
is regulated by SIRT1 inducing the gluconeogenic genes, 
phosphoenolpyruvate kinase and glucose-6-phosphatase by 
forming a protein complex with PGC-1α and hepatocyte 
nuclear factor (HNF)4α. Moreover, SIRT1 modulates 
the effects of PGC-1α repression of glycolytic genes, 
glucokinase and pyruvate kinase, acting the adenosine 
monophosphate (AMP)-activated protein kinase (AMPK) 
as the prime sensor that translates this information into 
SIRT1-dependent deacetylation (68-70), and also seems 
to activate fatty acid oxidation systemically by promoting 
adiponectin synthesis (71). SIRT1 deiciency in mice results 
in hyperglycemia, oxidative damage and insulin resistance 
and deicient animals become obese and insulin resistant 
when chronically challenged with a 40% fat diet, developing 
hepatomegaly.(71-73)
 Over the past decade, a number of evolutionarily 
conserved regulators and signaling pathways have been 
identiied for the control of aging and longevity. These 
regulators and signaling pathways, including insulin/IGF-
1 signaling (IIS) (74), mammalian target of rapamycin 
(mTOR) signaling (75), and NAD-dependent SIRT (61), 
provide excellent probes to dissect complex hierarchical 
mechanisms that affect the aging process and longevity in 
each model organism. Recent studies in worms and lies 
have also suggested that systemic interplay between multiple 
tissues regulates aging and longevity.(76,77) In mammals, 
however, the complexity of tissue interplay is multiplied, 
and a blueprint for a systemic network regulating aging and 
longevity still remains elusive.
 Alterations in NAD+ levels have a powerful metabolic 
impact because it serves as an obligatory substrate for the 
deacetylase activity of the SIRT proteins.(78-80) The best-
characterized mammalian SIRT is SIRT1, which controls 
mitochondrial function through the deacetylation of targets 
that include PGC-1α and FOXO.(81,82) The administration 
of NAD+ precursors, such as nicotinamide mononucleotide 
(83) or nicotinamide riboside (NR) (84), has proven to be an 
eficient way to increase NAD+ levels and SIRT1 activity, 
improving metabolic homeostasis in mice.(85) Considering 
the intimate link between metabolism and longevity (78,86), 
it was hypothesized that increasing NAD+ levels may be 
suficient to increase mitochondrial activity and extend 
lifespan (82).
 Sir2 is an NAD-dependent deacetylase that connects 
metabolism with longevity in yeast, worms and lies.
(9) Sir2 is required for lifespan extension by CR in yeast, 
worms, and lies.(87-89) In yeast, CR (0.5% glucose), was 
previously shown to increase mitochondrial function and to 
up-regulate Sir2 activity.(90,91) However, in this case, the 
mitochondrial activation is SIR2-independent, suggesting 
that it lies upstream of Sir2. A more severe CR regimen 
(0.05% glucose) extends yeast replicative lifespan by a 
different mechanism that is apparently independent of both 
Sir2 and mitochondrial respiration.(92,93)
 Stem cells, through their regenerative ability, 
maintain tissue homeostasis during an individual’s lifespan. 
However, stem cell-associated mechanisms of tissue repair 
become impaired with aging. Very interestingly, a recent 
study demonstrated that SIRT3, which is highly expressed 
in hematopoietic stem cells, is not essential for tissue repair 
at a young age under physiological conditions; however, 
it is crucial at an old age.(1) Moreover, it is important 
to highlight that induced SIRT3 overexpression, which 
is suppressed with aging, signiicantly improves aged 
hematopoietic stem cells’ regenerative power.(22) The 
plasticity of mitochondrial homeostasis controlling stem 
cell and tissue maintenance during the aging process and 
shows that aging-associated degeneration can be reversed 
by a SIRT.(22)
Resveratrol (3,5,4’-trihydroxystilbene) was irst isolated 
from the roots of white hellebore (Veratum grandilorum 
O. Loes) in 1940 (94), and later, in 1963 from the roots 
of Polygonum Cupsidatum, a plant used in traditional 
Chinese and Japanese medicine (95). However, the irst real 
interest in this compound came when in 1992 resveratrol 
was postulated to explain some of the cardioprotective 
effects of red wine (96) and was suggested to be an 
important factor in the French Paradox, a term coined to 
describe the observation that the French population has a 
very low incidence of cardiovascular disease, despite a diet 
high in saturated fat (97). Five years later, in 1997, Jang 
Therapeutic Potential of Resveratrol
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and colleagues reported resveratrol to work as a chemo-
preventive agent, by the ability to inhibit carcinogenesis 
at multiple stages.(98) Meanwhile, also anti-inlammatory 
and anti-oxidant properties were identiied for resveratrol.
(99,100) Interest in resveratrol peaked after 2003, when 
Howitz and colleagues (8) identiied resveratrol as a potent 
SIRT1 activator capable of mimicking the effects of calorie 
restriction (101,102) and regulating longevity in lower 
organisms, by extending lifespan in yeast (8), worms (103), 
lies (104,105) and in short-lived ish (106). Although there 
are a considerable amount of data supporting the role for 
resveratrol in SIRT1-mediated lifespan extension.(107)
 The exact mechanisms through which resveratrol 
exerts a wide range of beneicial effects across species and 
disease models is currently still unclear.(99) Similar to 
most other polyphenols, resveratrol is suggested to possess 
intrinsic anti-oxidant capacity, but it is also implicated to 
induce the expression of a number of antioxidant enzymes, 
with probably both mechanisms contributing to an overall 
reduction in oxidative stress.(108) Resveratrol further 
interacts with a large number of receptors, kinases, and other 
enzymes that could plausibly make a major contribution to 
its biological effects.(107)
 In mammals, there is growing evidence that resveratrol 
can prevent or delay the onset of cancer, heart disease, 
ischaemic and chemically induced injuries, diabetes, 
pathological inlammation and viral infection. These effects 
are observed despite extremely low bioavailability and rapid 
clearance from the circulation.(99)
 Resveratrol provides diverse health beneits including 
cardioprotection, inhibition of low-density lipoprotein, 
activation of nitric oxide (NO) production, hindering of 
platelet aggregation and promotion of anti-inlammatory 
effects. Studies have shown that at a lower dose, resveratrol 
acts as an anti-apoptotic agent, providing cardioprotection as 
evidenced by increased expression in cell survival proteins, 
improved post-ischemic ventricular recovery and reduction 
of myocardial infarct size and cardiomyocyte apoptosis and 
maintains a stable redox environment compared to control.
(109)
 In 1997, Jang  and colleagues published a seminal paper 
reporting the ability of resveratrol to inhibit carcinogenesis 
at multiple stages. Their inding that topical application of 
resveratrol reduced the number of skin tumours per mouse 
by up to 98% triggered research on resveratrol around the 
world.(98) Systemic administration of resveratrol has since 
been shown to inhibit the initiation and growth of tumours 
in a wide variety of rodent cancer models.(99) Jang and 
colleagues originally proposed that resveratrol might be 
an effective chemo-preventive agent because it inhibits the 
enzymatic activity of both forms of cyclooxygenase (COX).
(98)
 The in vitro studies indicate that transcriptional 
inhibition of COX2, as well as another important player in 
carcinogenesis, ornithine decarboxylase (ODC) could be 
accomplished through inhibition of protein kinase C (PKC).
(110,111) Resveratrol does not directly inhibit ODC activity 
(112), but reduces its expression in vivo and prevents its 
induction by carcinogens (113-115).
 Angiogenesis is required to support the growth of most 
solid tumours beyond a diameter of 2–3 mm. When delivered 
systemically at a dose of 2.5–100 mg per kg (body weight), 
resveratrol inhibits tumour-induced neovascularization.
(116,117) Resveratrol modulates the expression and activity 
of multiple drug-metabolizing enzymes. In vitro, resveratrol 
inhibits the enzymatic activity of various cytochrome 
P450 (CYP) (118-121) and blocks their transcription 
through antagonism of the aryl hydrocarbon receptor 
(AHR) (122,123), suggesting that resveratrol could cause 
a reduction in the exposure of cells to carcinogens. Another 
mechanism by which resveratrol could combat tumour 
formation is induction of cell cycle arrest and apoptosis. The 
anti-proliferative and pro-apoptotic effects of resveratrol in 
tumour cell lines have been extensively documented in vitro 
(124) and are supported by downregulation of cell cycle 
proteins (125-127) and increases in apoptosis (128-130) in 
tumour models in vivo.
 ROS have been shown to have a role in the initiation 
and progression of cancer through directly damaging DNA 
and other macromolecules.(131,132) In addition to its 
possible modulation of antioxidant enzymes involved in the 
Phase II response, resveratrol has an intrinsic antioxidant 
capacity that could be related to its chemopreventive effects. 
 In addition to its anticancer activity, resveratrol 
has displayed beneicial activity against inlammatory 
responses via inhibition of COX1 and COX2 expression.
(133) Resveratrol was reported to reduce the production 
of prostaglandin E2 (PGE2) and the formation of ROS 
in lipopolysaccharide (LPS)-activated microglial cells.
(134,135) Moreover, resveratrol was reported to suppress 
the activity of T- and B-cells, and macrophages.(136) 
Singh, et al., showed that resveratrol induced both caspase-
dependent and caspase-independent apoptosis in activated 
T-cells in experimental allergic encephalomyelitis- induced 
mice.(137) One study showed that resveratrol possesses 
analgesic property by inhibition of COX1 and COX 2.(138)
 Resveratrol also possesses neuroprotective properties. 
It has been reported that resveratrol could protect against 
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Figure 2. Trans-resveratrol and related structures. Piceid 
is found in grapes and other natural sources of resveratrol. 
Resveratrol-3-sulphate, resveratrol-3-O-glucuronide and 
dihydroresveratrol are metabolites of resveratrol.(99) (Adapted 
with permission from Nature Publishing Group).
Huntington’s disease (139), Alzheimer’s disease (140) and 
Parkinson’s disease (141).
 In rodent models of diet-induced obesity, a high dose 
of resveratrol (400 mg/kg/d) improves insulin sensitivity 
and lowers body weight (102), which has increased the 
interest and the speculation about its potential use as an 
anti-diabetic agent in humans. Nevertheless, recent work 
has shown that a one-year intervention with resveratrol at 
a dose of 200 mg/kg/d seems to cause an increase in basal 
metabolic rate and total daily energy expenditure in the non-
human primate Microcebus murinus (142,143); indicating 
that resveratrol might have the potency to enhance energy 
expenditure thereby promoting weight loss.
 Increased adventitial vasculogenesis is one of the 
pathological features of abdominal aortic aneurysm (AAA), 
and is thought to play an important role in the development of 
AAA, possibly through creating a conduit for inlammatory 
cell transport and establishing chronic inlammation in 
the aortic wall.(144) Resveratrol treatment resulted in 
downregulation of vascular endothelial growth factor 
(VEGF) A, a potent angiogenic and vascular permeability 
factor, and decreased neoangiogenesis in the aortic wall. 
The decreased neoangiogenesis by resveratrol treatment 
was associated with attenuation of macrophage iniltration 
and proinlammatory cytokines expression. Norata, et al. 
reported that resveratrol treatment reduced the expression of 
inlammatory markers and atherosclerotic plaque formation 
in apolipoprotein (Apo) E knockout mice.(145) Therefore, 
anti-angiogenic and anti-inlammatory effects of resveratrol 
may contribute to the prevention of AAA development.
(146)
 Published clinical trials have largely focused on 
characterizing the pharmacokinetics and metabolism of 
resveratrol. Recent studies have also evaluated safety and 
potential mechanisms of activity following multiple dosing, 
and have found resveratrol to be safe and reasonably well-
tolerated at doses of up to 5 g/day.(147) Though limited data 
is available on resveratrol’s eficacy in chronic metabolic 
diseases in humans, the clinical trials that are available show 
much promise that resveratrol might be applied to improve 
general health status and prevent chronic disease in humans.
Regardless of the established beneits of a CR diet, the 
severity of this dietary regime has limited adoption of this 
approach to increasing longevity, because few people can 
keep to such an unappealing lifestyle. It would therefore 
be desirable to provide an alternative route to obtaining 
the beneits of CR that would avoid the need for dietary 
regulation and that would be amenable to widespread 
use. The beneicial impact of increased SIRT1 activity 
observed in several animal models of disease has recently 
been observed in humans as well, where reduced SIRT1 
expression in insulin-sensitive tissues was associated with 
reduced energy expenditure.(148)
 Reversible acetylation is a key post-translational 
modiication of target proteins. SIRT deacetylases represent 
the homolog of the yeast Sir2. Although seven SIRT have 
been found in mammals, all SIRT activators described to 
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date act through SIRT1.(73) SIRT1 activators, with a focus 
on therapeutic applications, primarily related to the use of 
pharmaceuticals and nutraceuticals containing resveratrol, 
and the development of second-generation activators 
unrelated to resveratrol.(73)
 Resveratrol offers protection in models of stress- and 
age-associated diseases, including chronic overfeeding, 
insulin resistance, type 2 diabetes, and cardiovascular 
dysfunction.(101,102) The mechanisms behind these effects 
may rely on the fact that resveratrol mimics some of the 
Table 1.  Dietary Sources of Resveratrol.(99) ND: not determined. (Adapted with permission from Nature Publishing Group).
metabolic actions of CR, as a series of studies on humans 
have suggested.(107) Resveratrol interacts with many 
stress-related targets in the cell, including the mammalian 
NAD+-dependent deacetylase SIRT1 (99,102), although the 
resveratrol-SIRT1 interaction may be indirect (149). SIRT1 
is a member of a family of proteins (SIRT) that have been 
linked to longevity in yeast, lies, and worms.(9,85,150)
 A number of subsequent studies showed that 
resveratrol induced SIRT1 activity in several species.
(151) Furthermore, resveratrol mimics numerous aspects 
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Figure 3. Molecular Targets of Resveratrol: as a pharmacological 
agent, resveratrol has wide spectrum of targets.(109) (Adapted 
with permission from University of Massachussets).
of calorie restriction in all eukaryotes tested to date (8,101-
103,106,152,153) and in most of them, the effect appears 
dependent on SIRT1 (8,102,103).
 Resveratrol was also shown to increase energy 
expenditure in mice (101,102), through increased SIRT1 
activation, and during conditions of high fat availability, 
resveratrol was capable of preventing diet-induced obesity 
and the onset of obesity-related metabolic diseases, so 
ultimately protecting mice against the lifespan curbing 
effects associated with high calorie intake. The molecular 
mechanism underlying these beneicial effects seem to 
depend on the resveratrol-induced increase in mitochondrial 
content, which is explained by increased signaling through 
the SIRT1/ PGC1α axis.(102) More recently, some 
studies have questioned the direct activation of SIRT1 by 
resveratrol.(154,155)
 Several reports demonstrate that resveratrol can also 
activate AMPK (101,156-158), which reconciles with 
the positive effect on the mitochondrial respiratory chain 
that has been reported (159). Hawley, et al., reported that 
resveratrol-induced AMPK activation in isogenic cell lines, 
stably expressing AMPK complexes containing AMP-
insensitive γ2 subunit variants (R531G), derives from an 
AMP/ATP imbalance as a consequence of interference with 
mitochondrial respiration.(160) Although the idea was put 
forward that the resveratrol-induced AMPK activation was 
dependent on SIRT1 (161), the use of mouse embryonic 
ibroblast cells from SIRT1 knock-out mice unequivocally 
demonstrated that SIRT1 is dispensable for resveratrol-
induced AMPK activation (156,162). On the contrary, 
resveratrol cannot activate SIRT1 in the absence of functional 
AMPK.(162,163) So, the current working mechanism of 
resveratrol that evolved from all these reports is that SIRT1 
functions as the downstream mediator of AMPK, instead of 
being a direct molecular target of resveratrol. Canto, et al. 
(164) have shown in that respect that the AMPK induced 
increase in NAD+ levels, as a consequence of increased fatty 
acid oxidation, leads to SIRT1 activation.
 Diminished mitochondrial oxidative phosphorylation 
and aerobic capacity are associated with reduced longevity. 
Resveratrol’s effects were associated with an induction of 
genes for oxidative phosphorylation and mitochondrial 
biogenesis and were largely explained by an resveratrol-
mediated decrease in PGC-1α acetylation and an increase 
in PGC-1α activity. This mechanism is consistent with 
resveratrol being a known activator of the protein 
deacetylase, SIRT1, and by the lack of effect of resveratrol in 
SIRT1-/- mouse embryonic ibroblast (MEF). Importantly, 
resveratrol treatment protected mice against diet-induced-
obesity and insulin resistance.(102)
 The mechanisms by which enhanced autophagy 
can improve organismal health and longevity are largely 
elusive. As a possibility, increased autophagy might improve 
cellular resistance to stress by augmenting the metabolic 
buffering capacity of cells. Alternatively, autophagy might 
enhance organellar turnover and mediate a ‘cleaning effect’, 
thereby preventing the accumulation of damaged/old (and 
hence potentially harmful) mitochondria and lysosomes. 
Irrespective of these considerations, data establish the 
cardinal role of SIRT-1-elicited autophagy in mediating the 
anti-aging effects of CR and resveratrol.(10)
 SIRT1 activation restores bone marrow-derived early 
outgrowth cell (EOC) chemokine secretion and increases 
the in vitro and in vivo angiogenic activity of EOCs in 
diabetic animals. These indings suggest a pivotal role for 
SIRT1 in diabetes-induced EOC dysfunction and that its 
pharmacologic activation may provide a new strategy for 
the restoration of EOC-mediated repair mechanisms.(165) 
In fact, resveratrol treatment has been demonstrated to 
rescue adult stem cell decline, slow down bodyweight loss, 
improve trabecular bone structure and mineral density, and 
signiicantly extend the lifespan in zinc metallopeptidase 
STE24 (Zmp-ste24)-/- mice, which are deicient for Zmp-
ste24, a metalloproteinase responsible for prelamin A 
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maturation.(166)
 Over the past several years, chemically distinct 
molecules mimicking resveratrol effects were developed 
to activate SIRT at much lower doses.(167-169) Sirtris 
Pharmaceuticals identiied and characterized some small 
molecules designed to activate SIRT1 that are structurally 
unrelated to resveratrol. One of them, named SRT1720, was 
1000-fold more potent than resveratrol. Another strategy 
for SIRT activation is the use of agents that increase NAD+ 
concentrations and, consequently, potentiate mammalian 
SIRT functions. For example, increased intracellular NAD+ 
concentration has been shown to activate SIRT1 in brain, 
and has been proposed to help explain the protective effects 
of CR in a mouse model of Alzheimer’s disease.(170) 
Sauve and collaborators developed NR and derivatives that 
potently stimulate NAD+ biosynthesis in mammalian cells 
and thus, could provide an effective pharmacological means 
to increase SIRT activities.(171) Resveratrol is the best 
studied natural compound that is able to activate SIRT1. 
Synthetic drugs mimicking resveratrol and activating SIRT 
at much lower doses than resveratrol have been developed 
over the past several years.(73)
Figure 4. Molecular Targets for CR and Pharmacological Interventions against Premature Aging.(5) (Adapted with permission from 
Elsevier).
Conclusion
The natural polyphenolic compound resveratrol has received 
interest as several indings implicated resveratrol as a potent 
SIRT1 activator capable of mimicking the effects of calorie 
restriction, and regulating longevity in lower organisms. 
Given the worldwide increase in age-related metabolic 
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